In this issue:
- Salvage therapy/ASCT in R/R PMBCL after front-line DA-EPOCH-R
- PET-informed treatment de-escalation in DLBCL
- AN+AD in early-stage classical Hodgkin lymphoma
- 10-year follow-up of ibrutinib in CLL
- Prognostic stratification in AML treated with low-dose cytarabine + venetoclax
- Biomarkers in response-adapted daratumumab for transplant ineligible, newly diagnosed MM
- PANGEA-SMM: a model for risk stratification in smouldering MM
- BelaRd: belantamab mafodotin + lenalidomide + dexamethasone in transplant-ineligible, newly diagnosed MM
- Stem cell boost for prolonged cytopenias after CAR T-cell therapy in R/R MM
- CAREMM-001: BCMA CAR T-cell therapy in transplant-ineligible, newly diagnosed MM
Please login below to download this issue (PDF)